New test will run on Abbott's Alinity® i laboratory instrument, complementing Abbott's rapid i-STAT TBI Plasma test, cleared by the FDA in 2021 Given the significant number of Alinity i instruments in ...
Abbott Laboratories (NYSE:ABT) agreed to acquire Exact Sciences for US$21b. The deal is set to reshape Abbott's diagnostics business by adding a broad cancer testing platform. Management is also ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying ...
The R&D expansion in Illinois and Texas that Abbott Laboratories plans for this year will feed development of a next-generation blood testing device aimed at tapping a billion-dollar opportunity by ...
Abbott Laboratories’ financial results were negatively impacted by a sharp drop in COVID-19 test sales in Q1. The company’s market-beating dividend is well covered. The stock’s valuation appears to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results